US Army Medical Research Institute of Infectious Diseases
15
0
0
9
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 90/100
26.7%
4 terminated/withdrawn out of 15 trials
69.2%
-17.3% vs industry average
13%
2 trials in Phase 3/4
44%
4 of 9 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (15)
Combination HTNV and PUUV DNA Vaccine
Role: collaborator
The Female Microbiome in Patients Undergoing Bladder Instillation Therapy
Role: collaborator
FY15-14: Tularemia Vaccine Protocol (NDBR Lot 4)
Role: collaborator
Study of the Safety and Immunogenicity of Reduced Doses of the US Yellow Fever Vaccine
Role: lead
Venezuelan Equine Encephalitis Monovalent Virus-Like Particle Vaccine
Role: collaborator
Phase 2a Immunogenicity Study of Hantaan/Puumala Virus DNA Vaccine for Prevention of Hemorrhagic Fever
Role: collaborator
Safety and Immunogenicity of Venezuelan Equine Encephalomyelitis Vaccine in Healthy Adults
Role: collaborator
Safety and Immunogenicity Study of Recombinant Ricin Toxin A-Chain Vaccine (RVEc™)
Role: collaborator
IM Recombinant Ricin Toxin Vaccine (RVEc) - 3-Dose Primary Series With Boost
Role: collaborator
ID Recombinant Ricin Toxin A-Chain Vaccine RVEc™ - 3-Dose Primary Series With Boost
Role: collaborator
Safety and Immunogenicity of Q Fever Vaccine
Role: collaborator
A Non-inferiority Trial to Compare MVA-BN® Smallpox Vaccine to ACAM2000®
Role: collaborator
Chikungunya Arthritis in the Americas
Role: collaborator
Study of a DNA-based Venezuelan Equine Encephalitis Virus DNA Vaccine Administered by Electroporation in Healthy Volunteers
Role: collaborator
Study to Evaluate the Safety, Tolerability, and Immunogenicity of Hantaan and Puumala Virus DNA Vaccines
Role: collaborator
All 15 trials loaded